Novavax Stock Current Ratio
| NVAX Stock | USD 8.62 0.13 1.49% |
Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 0.70 | 0.66 |
Novavax | Current Ratio |
Novavax Company Current Ratio Analysis
Novavax's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Novavax Current Ratio | 1.05 X |
Most of Novavax's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novavax Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Novavax is extremely important. It helps to project a fair market value of Novavax Stock properly, considering its historical fundamentals such as Current Ratio. Since Novavax's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novavax's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novavax's interrelated accounts and indicators.
Click cells to compare fundamentals
Novavax Current Ratio Historical Pattern
Today, most investors in Novavax Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novavax's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novavax current ratio as a starting point in their analysis.
Novavax Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Novavax Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Novavax has a Current Ratio of 1.05 times. This is 63.92% lower than that of the Biotechnology sector and 85.0% lower than that of the Health Care industry. The current ratio for all United States stocks is 51.39% higher than that of the company.
Novavax Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.Novavax is currently under evaluation in current ratio category among its peers.
Novavax ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novavax's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novavax's managers, analysts, and investors.Environmental | Governance | Social |
Novavax Fundamentals
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (1.54) % | ||||
| Current Valuation | 704.57 M | ||||
| Shares Outstanding | 160.18 M | ||||
| Shares Owned By Insiders | 4.37 % | ||||
| Shares Owned By Institutions | 60.10 % | ||||
| Number Of Shares Shorted | 41.51 M | ||||
| Price To Earning | (1.36) X | ||||
| Price To Book | 49.52 X | ||||
| Price To Sales | 1.56 X | ||||
| Revenue | 983.71 M | ||||
| Gross Profit | (156.04 M) | ||||
| EBITDA | (487.39 M) | ||||
| Net Income | (545.06 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 16.31 X | ||||
| Total Debt | 229.08 M | ||||
| Debt To Equity | 8.24 % | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (3.29) X | ||||
| Cash Flow From Operations | (713.97 M) | ||||
| Short Ratio | 5.97 X | ||||
| Earnings Per Share | (2.18) X | ||||
| Target Price | 16.0 | ||||
| Number Of Employees | 1.54 K | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 1.38 B | ||||
| Total Asset | 1.8 B | ||||
| Retained Earnings | (4.82 B) | ||||
| Working Capital | (491.25 M) | ||||
| Current Asset | 287.26 M | ||||
| Current Liabilities | 76.49 M | ||||
| Net Asset | 1.8 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.